The adoptive transfer of T cells that are engineered to express chimeric antigen receptors
(CARs) has shown remarkable success in treating B cell malignancies but only limited …

Acute myeloid leukemia (AML) is a serious, life-threatening, and hardly curable
hematological malignancy that affects the myeloid cell progenies and challenges patients of …

Several tumour types are responsive to immunotherapy, as shown by regulatory approvals
for immune checkpoint inhibitors. However, many patients either do not respond or do not …

Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown
exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based …

Following immune attack, solid tumors upregulate coinhibitory ligands that bind to inhibitory
receptors on T cells. This adaptive resistance compromises the efficacy of chimeric antigen …

Chimeric antigen receptor T (CAR-T) cell therapy is an emerging and effective cancer
immunotherapy. Especially in hematological malignancies, CAR-T cells have achieved …

The field of gene therapy is striving more than ever to define a path to the clinic and the
market. Twenty gene therapy products have already been approved and over two thousand …

The timely reconstitution and regain of function of a donor-derived immune system is of
utmost importance for the recovery and long-term survival of patients after allogeneic …

The β-haemoglobinopathies, such as sickle cell disease and β-thalassaemia, are caused by
mutations in the β-globin (HBB) gene and affect millions of people worldwide. Ex vivo gene …

This review provides insight into the role of engineered T-cell receptors (TCRs) in
immunotherapy. Novel approaches have been developed to boost anticancer immune …